-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson’s RYBREVANT Combination Extends Survival To 34.3 Months In EGFR Exon 20+ Lung Cancer

Benzinga·09/14/2026 12:39:24
Listen to the news

https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer